ReviewFrontiers in immunology2020
A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool?
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Efficacy and safety of Chinese herbal medicine for atopic dermatitis: Evidence from eight high-quality randomized placebo-controlled trials.Frontiers in pharmacology · 2022Pooled it
- FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.Clinical drug investigation · 2022Trial
- Engineered etoposide-prednisolone co-nanocrystals for synergistic antitumor efficacy enhancement.Nanoscale advances · 2026Article
- Associated Autoimmunity in Myasthenia Gravis in Denmark: A Nationwide Case-Control Study.European journal of neurology · 2026Article
- Pulsed radiofrequency therapy ameliorates steroid-induced osteonecrosis of the femoral head by promoting nerve growth factor production.Cytotechnology · 2026Article
- Antiatopic dermatitis activity ofTurkish journal of biology = Turk biyoloji dergisi · 2026Article
- Predicting ICU Readmission in Patients With Cerebral Infarction: A Machine Learning Approach Using Neurophysiological and Clinical Data.Brain and behavior · 2025Article
- Steroid-Induced Thrombosis: A Comprehensive Analysis Using the FAERS Database.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases.Molecular therapy. Methods & clinical development · 2025Review
- VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies.International journal of molecular sciences · 2025Review
- High-Protein Diet Prevents Glucocorticoid-Induced Fat Mass Accumulation and Hyperglycemia.International journal of molecular sciences · 2025Article
- [Limitations and challenges of glucocorticoids in the treatment of paroxysmal nocturnal hemoglobinuria].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Disruption of Epithelial Barrier Integrity via Altered GILZ/c-Rel/RACK1 Signaling in Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2025Article
- Morpho-Functional Analyses Demonstrate That Tyrosol Rescues Dexamethasone-Induced Muscle Atrophy.Journal of functional morphology and kinesiology · 2024Article
- Trends in drug development for rare and intractable diseases based on the KEGG NETWORK.NAR molecular medicine · 2024Article
- The Application of Resveratrol Derivatives in Oral Cells Reduces the Oxidative Stress Induced by Glucocorticoids.Metabolites · 2024Article
- Effect ofMarine drugs · 2024Article
- Beneath the Surface: Exploring Hidden Threats of Long-Term Corticosteroid Therapy to Bone Density.Cureus · 2024Review
- Immunomodulation by glucocorticoid-induced leucine zipper in macrophages: enhanced phagocytosis, protection from pyroptosis, and altered mitochondrial function.Frontiers in immunology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their discovery, glucocorticoids (GCs) have been used to treat almost all autoimmune and chronic inflammatory diseases, as well as allergies and some forms of malignancies, because of their immunosuppressive and anti-inflammatory effects. Although GCs provide only symptomatic relief and do not eliminate the cause of the pathology, in the majority of treatments, GCs frequently cannot be replaced by other classes of drugs. Consequently, long-term treatments cause adverse effects that may, in turn, lead to new pathologies that sometimes require the withdrawal of GC therapy. Therefore, thus far, researchers have focused their efforts on molecules that have the same efficacy as that of GCs but cause fewer adverse effects. To this end, some GC-induced proteins, such as glucocorticoid-induced leucine zipper (GILZ), have been used as drugs in mouse models of inflammatory pathologies. In this review, we focus on some important but rare autoimmune and chronic inflammatory diseases for which the biomedical research investment in new therapies is less likely. Additionally, we critically evaluate the possibility of treating such diseases with other drugs, either GC-related or unrelated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.